Multiparameter Patient Monitoring - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

GlobalData’s new report, “Multiparameter Patient Monitoring - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017” provides key data, information and analysis on the global multiparameter patient monitoring market. The report provides market landscape, competitive landscape and market trends information on the multiparameter patient monitoring market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market’s dynamics. The report also reviews the competitive landscape and technology offerings.

Multiparameter Patient Monitoring Market

Published:January 2012
No. of Pages: 73

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

• Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
• Key segments covered include High Acuity Monitors, Low Acuity Monitors, Mid Acuity Monitors and Multiparameter Central Stations.
• Annualized market revenues data from 2003 to 2010, forecast forward for seven years to 2017. Company shares data for 2010.
• Qualitative analysis of key market trends, market drivers, and restraints within the multiparameter patient monitoring market.
• The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
• Key players covered include Philips Healthcare, GE Healthcare, Draegerwerk AG & Co. KGaA and Mindray Medical International Limited.

Reasons to buy

• Develop business strategies by understanding the trends and developments that are driving the multiparameter patient monitoring globally.
• Design and develop your product development, marketing and sales strategies.
• Develop market-entry and market expansion strategies.
• Identify key players best positioned to take advantage of the emerging market opportunities.
• Exploit in-licensing and out-licensing opportunities by identifying products that are most likely to ensure a robust return.
• What’s the next big thing in the multiparameter patient monitoring market landscape? – Identify, understand and capitalize.
• Make more informed business decisions from the insightful and in-depth analysis of the global multiparameter patient monitoring market and the factors shaping it.

Food Preservatives Market by Types, Functions, & Applications, Trends & Global Forecasts (2011 - 2016)

The report provides full analysis of the world’s leading players in the food preservatives segment, the key ingredients occupying the major shares, with a clear insight and commentary on the developments and trends. Also included is a chronology of developments with respect to product, function, and applications; ensuring coverage of the latest findings in the preservation technology. With the huge market potential and growth, market is likely to witness a shift in the variants and methods of food preservation. The market is anticipated to continue flourishing in the developed as well as the developing regions. The growth is also attributed to the growing demands and penetration of the organic food products. The variants and combination methods used for the preservation are bound to undergo further developments with growing demands and concerns for food safety legislations and regulations.

Food Preservatives Market

Published:January 2012
No. of Pages: 280

Sample Key Highlights:

The global food preservative market is estimated to be at $2.5 Billion by 2016, growing at a CAGR of 2.5%, essentially boosted by the fast growth amongst natural preservatives. North America stands the largest market followed by Asia-Pacific with a considerable market share. The emerging markets within Asia-Pacific, such as China and India drive the high growth rate. The growth of 2.2% in Europe is dependent heavily on the natural preservatives. The CAGR in Europe is mainly driven by the fast growth in natural preservatives segment. The high growth within Europe is in Germany, France, U.K., and Italy. North America and Asia-Pacific together contribute close to 70% in the global food preservatives market.

Scope of the report
This report focuses on global food preservatives market. This research categorizes the global food preservatives market on the basis of types, applications, geography:

On the basis of types:
Natural
Artificial

• Sorbates
• Benzoates
• Propionates
• Others (nitrites, sulphites, lactates, acetates)

On the basis of functions:

• Antimicrobials
• Antioxidants
• Others

On the basis of applications:

• Oils/Fats
• Bakery products
• Dairy and frozen foods
• Snack foods
• Meat, poultry and seafood
• Confectionery and condiments
• Beverages
• Others

On the basis of geography:

• North America
• Europe
• Asia-Pacific
• ROW

Endpoints - Clinical trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success

GBI Research, the leading business intelligence provider, has released its latest research Endpoints – Clinical Trials in Cardiovascular Disorders – Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success which provides an insight into the different endpoints that are used in cardiovascular clinical trials. The report examines various aspects of clinical trial endpoints in cardiovascular disorders, such as analysis of the major marketed cardiovascular drugs, with an emphasis on safety and efficacy details, Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, the most promising cardiovascular drugs in the therapeutic pipeline with details on safety, efficacy and clinical trials, and terminated trial analysis. The report also includes company profiles that highlight the cardiovascular drugs of different companies. Cardiovascular disorders represent a collective group of disorders that affect the functioning of the heart and the blood vessels. These disorders are one the most prevalent groups of disorders in the world today, and represent a significant proportion of the world’s total diseased population. Most of them cause significant morbidity and disability.

Clinical trials in Cardiovascular Disorders

Published:January 2012
No. of Pages: 152

The global cardiovascular therapeutics market was valued at $93.5 billion in 2010 and expected to reach revenues of $115.6 billion by 2017 with a CAGR of 3.1%. Approximately 127 million patients received pharmacological treatment for their cardiovascular diseases in 2011 with average cost of therapy being $596 per year. In addition, the average annual cost of therapy for the cardiovascular diseases therapeutic area appears likely to increase at a gradual rate over the next one to two years, with an expected price decline in 2011 onwards. This report details the endpoints in clinical trials for cardiovascular disorders, highlighting the five major cardiovascular disorders, which are atherosclerosis, atrial fibrillation, dyslipidemia, hypertension and venous thromboembolism. The classification of five major cardiovascular diseases is done on the basis of the number of pipeline molecules present in Phase III of development. The term endpoint refers to an outcome or measure of a clinical trial. Endpoints can include all kinds of aspects, such as those related to the effectiveness of treatment as well as other factors. However, endpoint selection must take into account the need to obtain the highest information of therapeutic interest with the least risk and discomfort for the individual. Also, the endpoints must be important to the objective of the study and represent the most effective way to assess pharmacological response.

Scope

• Data and analysis on the marketed products and analysis of their efficacy and safety details.
• Analysis of the five major cardiovascular diseases which include atherosclerosis, atrial fibrillation, dyslipidemia, hypertension and venous thromboembolism.
• Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Also analysis of terminated trials is included in this chapter. Only industry sponsored studies are included in the report.
• Analysis on most promising molecules of five major cardiovascular diseases with emphasis on their efficacy and safety details.
• Company profiling talks in detail about the companies, which are strong in the market.

Respiratory Measurement Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017

GlobalData’s new report, “Respiratory Measurement Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017” is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The emerging economies, comprising China, India, Brazil, Russia and South Africa, with a significantly large pool of under-served patients, represent the next big opportunity for the leading medical equipment and devices manufacturers. China remains the world’s most populous country and is consequently home to a large patient base. The country is home to more than 120 million people who are aged 65 or older—a population in continuous need of medical care. India, the second most populous country globally, is home to 1.2 billion people, approximately 5% of which are aged 65 or older. It’s estimated that shortly after 2020, India’s population will surpass China, making it the most populous country in the world. As the population continues to grow and people continue to age, the underlying demand for healthcare is also expected to increase.

Respiratory Measurement Devices Market Outlook 

Published:January 2012
No. of Pages: 215

This report provides key market data on the Respiratory Measurement Devices market in the BRICS countries. The report provides value ($m), volume (units) and average price ($) data for each segment and sub-segment within three market categories – Pulse Oximeter Systems, Spirometers and Capnograph. The report also provides company shares and distribution shares data for the overall Respiratory Measurement Devices market in each of the aforementioned countries. The report is also supplemented with global corporate-level profiles of the key market participants with information on key developments, wherever available.
Scope

• Market size data for Respiratory Measurement Devices market categories – Pulse Oximeter Systems, Spirometers and Capnograph.
• Annualized market revenues ($m), volume (units) and average price ($) data for each of the segments and sub-segments within the three market categories. Data from 2003 to 2010, forecast forward for seven years to 2017.
• 2010 company shares and distribution shares data for the overall Respiratory Measurement Devices market in each of the aforementioned countries.
• Global corporate-level profiles of key companies operating within the Respiratory Measurement Devices market in BRICS.
• Key players covered include Covidien plc, Draegerwerk AG & Co. KGaA, Masimo Corporation, Smiths Medical, Philips Respironics, Inc., GE Healthcare, CareFusion Corporation, Nonin Medical, Inc. and Invacare Corporation.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Respiratory Measurement Devices competitive landscape in BRICS.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Coal Seam Gas (CSG/CBM) in Asia, 2011 - Market Analysis, Investment Scenario, Competitive Landscape and Production Forecasts to 2015

The report provides detailed information and analysis of CSG/CBM market in Australia, China, India, Indonesia and Vietnam. The report primarily focuses on -

• Major growth drivers and challenges for development of CSG/CBM resources in Australia, China, India, Indonesia and Vietnam.
• Various exploration projects, major companies engaged in CSG exploration and production. Projected CSG/CBM production by 2015 for Australia, China, India and Indonesia.
• Overall CSG scenario in Australia including, reserves, production and major basins with CSG potential including Australia CSG fiscal regulations.
• Overall CBM scenario in China including, reserves, production, major government policies and targets.
• Overview of CBM in India with key reserves and production and detailed policy measures and CBM exploration rounds.
• Status of CBM exploration in Vietnam and key companies engaged in CBM exploration.
• CSG/CBM Production forecast for the period 2011–2015 for Australia, China, India, Indonesia and Vietnam.
• CBM scenario, CBM reserves and basins of Indonesia including policy measures and various companies engaged in CBM operations.

Coal Seam Gas (CSG/CBM) in Asia Market Forecasts

Published:January 2012
No. of Pages: 77

This is the latest report from industry analysis specialists offering comprehensive information on the Asian Coal Seam Gas market, covering Australia, China, India, Indonesia and Vietnam. The report provides information on the coal seam gas and coal bed methane overall scenario, reserves, exploration, production, production forecast and status of CSG/CBM projects. The research also provides an in depth analysis of the CSG/CBM basins, fiscal policies, trends and competitive landscape of key CSG/CBM assets.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Identify potential investment targets based on the exhaustive information on reserves, production, government policies and ongoing projects, supported by in-depth analysis on each of the CBM markets in Asia.
• Take prompt and effective business decisions supported by forecasts and well-researched analysis of the top CBM Markets in Asia.
• Devise business strategies based on the competitive structure of the markets if expanding or entering into the CBM market in Asia.
• Gain insights into competitors’ endeavors based on their operations and planned projects.
• Identify opportunities to partner with companies operating in these expanding markets.The report will help in to:
• Develop business strategies with the help of specific insights into Asia’s coal bed methane/ coal seam gas exploration and production market.
• Identify opportunities and challenges in the CSG/CBM industry, especially the policy and regulatory structures.
• Understand the policy landscape and fiscal regulations on CSG/CBM development in Australia, China, India and Indonesia.
• Increase future revenue and profitability with the help of insights into future opportunities and critical success factors in the CSG/CBM industry.
• Identify the opportunities to partner with the major players and enter this prolific investment destination.
• Make smart investment decisions in the CSG/CBM markets by leveraging on our detailed insights into the industry.

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017, a new report by Global Markets Direct, provides key market data on the Greece In Vitro Diagnostics market. The report provides value (USD million), for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on key recent developments. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Direct’s team of industry experts.

Greece In Vitro Diagnostics Investment Market

Published:January 2012
No. of Pages: 145

Scope

• Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
• Annualized market revenues (USD million) for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017.
• 2010 company shares and distribution shares data for each of the seven market categories.
• Global corporate-level profiles of key companies operating within the Greece In Vitro Diagnosticsmarket.
• Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., bioMerieux S.A. and others.

Reasons to Buy

Develop business strategies by identifying the key market categories and segments poised for strong growth.Develop market-entry and market expansion strategies.Design competition strategies by identifying who-stands-where in the Greece In Vitro Diagnostics competitive landscape.Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Asia-Pacific Smart Grids Market to 2020 - Government Initiatives and Longer-Term Strategic Focus of Utilities Will Determine Future Uptake

GBI Research, a leading business intelligence provider, has released its latest research, “Asia-Pacific Smart Grids Market to 2020 - Government Initiatives and Longer-Term Strategic Focus of Utilities Will Determine Future Uptake”. The report gives an in-depth analysis of the Asia Pacific (APAC) smart grid market, covering three major technologies: smart meters, synchrophasors and Remote Terminal Units (RTUs). The report covers the cumulative installed units and revenue from 2010-2020 for the three technologies for Australia, China, India, New Zealand, the Republic of Korea, Indonesia and Malaysia. The report also provides the competitive analysis of RTUs for Indonesia and Malaysia installed in 2010. The report provides the policies and regulations surrounding smart grid for China, India, Australia, Japan and New Zealand.

Smart Grids Market

Published:January 2012
No. of Pages: 104

Scope
The report provides detailed analysis and forecasts on the APAC smart grid market. Its scope includes -

• The APAC smart grid market analysis covering three major technologies: smart meters in China, Australia and the Republic of Korea; synchrophasors in China, India and New Zealand; and RTUs in Indonesia and Malaysia.
• Historical and forecast of number of units installed and revenue for smart meters, synchrophasors and RTUs from 2008-2020.
• Smart grid policies and incentives for China, Japan, Australia, New Zealand and India.
• Global smart grid market analysis, technology analysis, technology deployments and drivers and restraints.
• APAC smart grid market trends and market analysis.
• APAC smart grid market deals analysis such as mergers, acquisitions, partnerships, venture capitals, debt finances and equity offerings.
• APAC smart grid market major contracts and major projects.

Reasons to buy
This report is a useful tool for industry professional to help them to -

• Develop business strategies and future plans with the help of the country wise understanding of the Asia Pacific smart grid market.
• Make more informed business decisions from the insightful and in-depth analysis armed with hard-to-get value and volume data of the Asia Pacific Smart Grid Market and the factors shaping it.
• Assess the impact of new entrants and more cost-effective products in key markets
• Identify emerging markets and investment opportunities in both general and niche markets
• Enhance product development, marketing and sales strategies equipped with insights into critical success factors of leading manufacturers.

Veterinary Vaccines Market to 2017 - Europe to Strengthen Its Position as the Single Largest Market for Animal Vaccines Due To Highly Organized Livestock Farms

GBI Research analyzes the veterinary vaccines market up to 2017. The report examines the market by analyzing livestock species including bovine, ovine, equine and porcine. The target population considered is the total animal population in each respective region. The report specifically covers livestock species excluding companion animals, and concludes that the livestock market sector has shown steady growth in recent years. Biotechnology developments and research contributed tremendously towards the growth and enhancement of the veterinary vaccines market. Europe and the US collectively hold more than 70% of the total market.

Veterinary Vaccines Market

Published:January 2012
No. of Pages: 76

The market grew at a steady rate for the past few years and is expected to grow further. The demand for veterinary vaccines in the market is driven by factors such as the vulnerability of animals to fatal and chronic diseases, and the changing patterns of the diseases. The recent epidemics created awareness among livestock owners of the need to avoid the huge production losses due to diseases such as swine flu, avian influenza and anthrax. The future of vaccines will be dominated by DNA-related vaccines and combination vaccines, which can provide protection against various diseases with minimal vaccine shots. Such innovative products will be more capable of providing protection and generating a strong immune response than the traditional vaccines.

The key players in the veterinary vaccines market are Bayer HealthCare, Merck & Co. Inc., Fort Dodge Animal Health, Novartis Animal Heath, Pfizer, Lohmann Animal Health, Merial Ltd., Boehringer Ingelheim GmbH, and Heska Corporation. There are many other companies which are involved with the manufacturing and development of veterinary vaccines apart from those in the list.

Scope

• Annualized market data for the veterinary vaccines market from 2002 to 2010, forecast forward to 2017.
• Analysis of the leading livestock segments, including bovine, ovine, porcine and equine.
• Analysis of the veterinary vaccines market in the leading geographies of the world, which include the US, Europe and Japan.
• Market characterization of the veterinary vaccines market, including market size, annual cost of vaccination and target population.
• Key drivers and barriers that have a significant impact on the market.
• Competitive benchmarking of leading companies. The key companies studied in this report are Bayer, Pfizer, Merck and Novartis.
• Key M&A activities and licensing agreements that have taken place in the veterinary vaccines market.

Solid Organ Transplant Immunosupressants Market to 2018 - Limited Availability of Donors Drives Improvements in Organ Procurement and Preservation Methods

GBI Research, the leading business intelligence provider, has released its latest research, Solid Organ Transplant Immunosuppressant Market to 2018 – Limited Availability of Donors Drives Improvements in Organ Procurement and Preservation Methods, which provides insight into the global solid organ transplant immunosuppressant drug market until 2018. The report provides an in-depth analysis of the following five transplant areas: heart, lung, pancreas, liver and kidney. It also details immunosuppressant drug markets in the following key regions: the US, the top five countries of Europe and Japan. The report also includes details about immunosuppressant drug R&D pipelines.

Solid Organ Transplant Immunosupressants Market

Published:January 2012
No. of Pages: 87

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts. GBI Research analysis shows that the global market for immunosuppressant drugs used in transplants is projected to increase at a compound annual growth rate (CAGR) of 6.7% from 2004–2010. The market is forecast to grow at a CAGR of 6.1% from 2010–2018, to reach a value of $5.6 billion in 2018. GBI Research analysis found the R&D pipeline for the immunosuppressant drug market to be moderate. The leading companies in this market, F. Hoffman La Roche, Novartis AG, Genzyme Corporation and Astellas Pharma Inc., are also analyzed in this report.

Scope

• Analysis of the five major solid organ immunosuppressant drugs market which include heart transplant, pancreas transplant, lung transplant, kidney transplant and liver transplant immunosuppressant drug market
• Data and analysis of the immunosuppressant drug market in the leading regions of the world: the US, the top five countries of Europe and Japan.
• Annualized market data for the immunosuppressant drug market from 2004–2010, with forecasts to 2018.
• Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and target populations.
• Key drivers and restraints that have had a significant impact on the market.
• Pipeline analysis of the immunosuppressant drug market for the five types of transplant.
• Competitive landscape of the global immunosuppressant drug market including benchmarking of top companies. The key companies studied in this report are: F. Hoffman La Roche, Novartis AG, Genzyme Corporation and Astellas Pharma Inc.

Reasons to Buy

• The report will aid business development and help marketing executives strategize product launches, and:
• Build effective strategies to launch pipeline products by identifying potential geographies.
• Develop key strategic initiatives by studying the key strategies of top competitors.
• Develop market entry and market expansion strategies by identifying geographic markets poised for strong growth.
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with better efficacy and safety.

2012 Deep Research Report on China Wind Power Converter Industry

This report on China's Wind Power Converter market is published by QYResearch Wind Energy Research Center in Jan 2012. It is a 126 pages report with 152 Tables & Figures.

It is a professional and in-depth research report on China Wind Power Converter Industry. We focus on China's domestic market in this report and make a comprehensive and objective reflection of the status of China's current wind Power Converter industry. Including wind Power Converter definition classification working principal, we analysis Wind Power Converter production process and production Model technology parameters；Statistics 9 foreign and 18 domestic Wind Power Converter manufacturers Wind Power Converter production（Double-fed & Full power）,（850KW 1.25MW 1.5MW 1.65MW 2.0MW 2.5MW 3.0MW 3.6MW etc.）Capacity Production Cost price Profit industry value Profit Margin etc.

Wind Power Converter Industry

Published:January 2012
No. of Pages: 126

We also made a statistic of those manufacturers Wind Power Converter product client（wind turbine assembly companies）equipment raw material and company background information，then we add up these data and come to a conclusion analysis，including China Wind Power Converter capacity Market share，production Market share，every wind Power Converter manufacturers Capacity Production market share，850KW 1.25MW 1.5MW 1.65MW 2.0MW 2.5MW 3.0MW 3.6MW etc. Capacity Production Market share，Double-fed & Full power（Direct drive wind turbine） Converter production market share，850KW 1.25MW 1.5MW 1.65MW 2.0MW 2.5MW 3.0MW 3.6MW etc. converter demand and shortage, Wind Power Converter 2009-2016 Capacity Production Price Cost Profit output value Profit Margin etc.

Finally we made a detailed analysis of the investment feasibility of 400sets/year 1.5MW or above wind Power Converter project，we draw a research conclusion of China wind Power Converter industry. In a word, it was a depth research report on china Wind Power Converter industry. And thanks to the China Wind Power Converter wind turbine and IGBT marketing or technology experts help and support during QYResearch Wind Energy team survey and interviews.

2012 Deep Research Report on Global and China CIGS Thin Film Solar Cell Industry

This report analyzes the Global and China CIGS Thin Film Solar Cell Industry through 8 chapters &150 Tables & Figures relevant to the market - all covered in 164 pages.

It is a professional and in-depth research report on CIGS Solar Cell Industry. Firstly the report describes the background knowledge of CIGS Solar Cell (CIS CIGS), including Concepts Classification Manufacturing process technical parameters etc; then statistics International 22 and China 6 Manufacturers CIGS Solar Cell product Capacity production cost price production value profit margins and other relevant data, statistics these enterprises CIGS Solar Cell products, customers, raw materials, company background information, then summary statistics and analysis the relevant data on these enterprises

CIGS Thin Film Solar Cell Industry

Published:January 2012
No. of Pages: 164

The report got Global and China CIGS Solar Cell companies production market share, Global and China CIGS Solar Cell demand supply and shortage, Global and China CIGS Solar Cell 2009 -2016 production price cost profit production value profit margins, etc.

At the same time, the report analyzes and discusses supply and demand changes in CIGS Solar Cell market and business development strategies, conduct a comprehensive analysis on Global and China CIGS Solar Cell industry trends. Finally, the report also introduced 100MW/year CIGS Solar Cell project Feasibility analysis and related research conclusions. In a word, It was a depth research report on Global and China CIGS Solar Cell industry. And thanks to the support and assistance from CIGS Solar Cell industry chain related experts and enterprises during QYResearch Solar Energy Research Team survey and interview.

Major points covered in Table of Contents of this report include

Chapter One CIGS Thin Film Solar Cell Overview
Chapter Two Manufacture Technology and Processes of CIGS Thin Film Solar Cell
Chapter Three CIGS Thin Film Solar Cell Productions Supply Sales Demand Market Status and Forecast
Chapter Four CIGS Manufactuers
Chapter Five CIGS Building and Planing Projects
Chapter Six CIGS Equipment Suppliers
Chapter Seven Feasibility Analysis of China CIGS Solar Module Project
Chapter Eight CIGS Solar Cell Industry Research Conclusions
Tables and Figures

Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules

GBI Research, the leading business intelligence provider, has released its latest research “Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules”, which provides insights into global antipsychotic market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the antipsychotics market for bipolar disorder and schizophrenia. The report also provides the share of generics in global antipsychotic market as well as in each indication market. The report examines the global bipolar disorder and schizophrenia treatment usage patterns. In addition, geographical distribution of antipsychotic market across the US, the top five countries of Europe and in Japan. The report also includes insights into the antipsychotics R&D product pipeline and explores the competitive landscape including major players in antipsychotics market. Finally, the report also includes analysis on Mergers and Acquisitions (M&A) and licensing agreements that took place in antipsychotics market.

Antipsychotics Market

Published:January 2012
No. of Pages: 87

Scope

• Data and analysis on the antipsychotic market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
• Annualized market data for the antipsychotics market from 2002 to 2010, with forecasts to 2017.
• Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
• Share of the generics in global antipsychotics market and for the market of each indication that is covered in the report.
• Key drivers and restraints that have had a significant impact on the market.
• The competitive landscape of the global antipsychotic market including top companies benchmarking. The key companies studied in this report are Eli Lilly, Pfizer, Astra Zeneca, Bristol-Myers Squibb and Johnson & Johnson.
• Key M&A activities and Licensing Agreements that took place in 2009 and 2010 in the antipsychotics market.

Reasons to Buy

• Align your product portfolio to the markets with high growth potential.
• Build effective strategies to launch their pipeline products by identifying potential geographies.
• Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
• Develop key strategic initiatives by studying the key strategies of top competitors.
• Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
• Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Smartphones: New User Paradigms and Behaviors

The Smartphone market is currently the fastest-growing segment and it will continue to outpace the overall handset market for the foreseeable future. User friendly platform and evolving user behavior pattern are responsible for its exponential growth. In the past few years Smartphone sales have grown exponentially. In 2011, 472 million Smartphone were sold worldwide. This is expected to rise to 1 billion by 2016. Smartphones now account for 17% of all global mobile handset sales. Particularly in the USA, 43% end-users have Smartphone which is equivalent to France, Germany, Italy, Spain and the UK.

Among the four major operating platforms Android leads the market with 47% market share beating Apple's who has 29%. However 57% mobile operating profits are in Apple's basket. The user behavior pattern has also experienced a major shift from voice to data centric in last year and sleek design of handset. Usage and growth in social networking, mobile payments, and many expected other non-voice applications driven by LTE are expected.

Smartphones: New User Paradigms and Behaviors

Published:January 2012
No. of Pages: 231

This research addresses:

• Top Smartphones and innovations in 2011
• Smartphone user behavior pattern evolution
• Top smartphone functions for end-users
• Relationship between mobile growth and smartphone user behaviors
• Leading demographics (by gender / race / nationality) for usage
• New dynamics of smartphone user behavior
• Impact of mobile marketing
• Relationship of applications market to smartphone user behavior
• Smartphone business models
• Actions that stakeholders should take for optimal success in smartphone marketplace

Key Findings:

• We project 20% of smartphones will support NFC by 2014
• Mobile commerce will become $31 billion business by 2016
• We see 74% of mobile search leading to a purchase because of smartphone
• Mobile marketing spend will reach $56.5 billion in 2015
• Statistical snapshots:

1. 50% smartphone users purchase via mobile
2. 45% of smartphone users check email constantly throughout the day
3. 32% of smartphone users check Facebook at least once per day
4. 78% of Japanese smartphone users browse online from their mobile
5. 90% of smartphone users search local information in US and Japan
6. 76% of smartphone users utilize location check-in services
7. 56% of smartphone usage is with applications
8. 60% of end-users connect to social networks via mobile

Global and China Plastic Packaging Industry Report, 2010-2012

In the global plastic packaging industry, the CAGR was roughly 7.2% between 2001 and 2010, featuring the fastest growth in packaging industry breakdown. For China, the market scale of plastic packaging industry approximated USD66.4 billion in 2011, accounting for 31.2% of the total worldwide. Currently, the growth in the output of plastic packaging is in proportion to the growth of demand, with the overall industry presenting a balanced supply-demand situation.

Plastic Packaging Industry

Published:January 2012

No. of Pages: 86

Operating Features of China Plastic Packaging Industry

• Low Industrial Concentration: the top five businesses in plastic flexible packaging industry accounted for 19.4% market share in 2010. In particular, Huangshan Novel Co., Ltd. was the champion, with the market share making up 7.2%. And the top five businesses in cosmetic plastic packaging industry stood at 26% market share. In particular, Shenzhen Beautystar Company Limited occupied a lion’s share of 8.6%.
• Pharmaceutical Packaging Expecting to Become New Contributor for the Growth of Plastic Packaging Industry: in terms of downstream sectors, plastic packaging witnesses the widest application in consumer goods industries like foods & drinks, daily chemical articles and pharmaceutical industries. In 2010, the application of plastic packaging in downstream foodstuff industry, daily chemical articles, pharmaceutical industry and others made up around 70%, 13%, 9%, and 8%, respectively. In developed countries, pharmaceutical packaging occupies 30% of the value of the medicines, while the figure in China is less than 10%. Hence, China pharmaceutical packaging industry is expected to see skyrocketing development in upcoming years.
• Plastic Wire, Rope & Knitting Seeing Rapid Growth in Output: among all the plastic packaging materials, the output of plastic film is the highest, while the output of plastic wire, rope and woven products among the subdivided products has seen the fastest growth. For example, the average output growth of plastic wire, rope and woven products in 2005-2010 reached 24.8%, compared with 13.1% and 13.5% for plastic film and plastic packaging container respectively.

HIV-AIDS Testing Markets

There are an estimated 33.3 million people living with HIV (the virus which causes AIDS) worldwide and approximately 2.6 million people are newly-infected each year. While the Asian and African regions account for more than 90% of the HIV-infected population (with the highest number in Sub-Saharan Africa), the U.S. and European regions make up greater than 60% of the HIV testing market. This TriMark Publications report provides a comprehensive examination of the HIV/AIDS testing market, a specific segment of the in vitro diagnostics (IVD) market as it relates to infectious diseases. It examines the available and emerging technologies being utilized by the HIV testing field, defines the dollar volume of sales—both in the U.S. and worldwide—and analyzes the factors that influence the size and growth of the market.

HIV-AIDS Testing Markets

Published:January 2012
No. of Pages: 131

The chief HIV testing assays, i.e., predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic, are covered thoroughly, as are high-growth applications in different clinical diagnostic areas and expanding markets, such as employee screening, emergency medicine and satellite clinic testing. Additionally, this analysis covers the following areas in details: enzyme-linked immunosorbent assay (ELISA), antibody/p24 antigen test (fourth-generation test), Western blot assay, line immunoassays, indirect fluorescent antibody (IFA) assay, nucleic acid tests for infectious diseases, and the emerging technologies related to HIV and AIDS diagnosis. Moreover, this study also provides a thorough analysis of the companies known to be marketing, manufacturing or developing HIV testing products, as well as provides detailed tables and figures covering HIV testing markets around the globe.

Major points covered in Table of Contents of this report include

1. Overview
2. Overview of HIV and AIDS
3. Profile of HIV/AIDS: Statistics and Epidemiology
4. Overview of HIV Testing
5. Technological Platforms Used in HIV Testing
6. Issues Affecting HIV Testing
7. HIV Tests on the Market
8. Market Analysis: Size, Growth, Share and Competitors
List Of Tables
List Of Figures

Mobile Payment in China: 2011-2012 Edition

Mobile Payment in China: 2011-2012 Edition is the fifth and latest edition of our most popular report. Simply put, it is the most up-to-date and comprehensive study available on China's mobile payment sector today. The report focuses on the top issue for m-payment in China in 2011: government licensing for "non-financial institutions". In this report we profile all of the companies to have received mobile payment licenses; they include many of China's leading third-party payment providers, as well as new m-payment specialists, provincial payment processors, telecom operators, and payment-related software and equipment providers.

Mobile Payment Market

Published:January 2012
No. of Pages: 81

Mobile Payment in China: 2011-2012 Edition includes updated coverage on leading mobile payment business models, technologies, and services. In addition, we examine the key issues affecting the market heading into 2012 and forecast growth and major changes through 2015.

Key Topics: 

Mobile payment licenses: coverage of all companies that received them, how they are being enforced, and how they will change the industry
China's post-licensing market landscape: how China's operators, banks, and other payment powerhouses are adjusting
NFC and contactless mobile payments
Mobile apps and app stores
M-payment global leaders' strategies for breaking into China's payment market

Companies Covered
Third-party mobile payment providers: Alipay, China UnionPay (ChinaPay), Tenpay, Union Mobile Pay (UMPay), 47Pay, 99Bill, Chinabank Payments, IPS, Lianlian Pay, MoBo, Qiandai, SandPay, Shanghai FFT, Smartpay, Yeepay, Yinsheng E-Pay
Mobile operators: China Mobile, China Telecom, China Unicom
Banks: Bank of China, China Construction Bank, Agricultural Bank of China, Industrial and Commercial Bank of China (ICBC), China Minsheng Bank, China Merchants Bank, Bank of Communications, Shanghai Pudong Development Bank, China CITIC
Foreign m-payment leaders in China: Apple, Google, Isis, Mastercard, PayPal, Square, Visa

Metamaterials: Technologies and Global Markets

• BCC estimates the global market for metamaterials was worth $222.3 million in 2010 and $256.1 million in 2011. BCC expects the market to grow to $758.7 million by 2016, a compound annual growth rate (CAGR) of 24.3% since 2011, and to reach nearly $1.9 billion by 2021, a CAGR of 19.6% between 2016 and 2021.
• The Electromagnetic segment of the market was estimated to be worth $140 million in 2010 and $160.6 million in 2011. BCC expects the market to grow to $412.2 million by 2016, a CAGR of 20.7% since 2011, and to reach nearly $1.2 billion by 2021, a CAGR of 23.5% between 2016 and 2021.
• The extreme-parameter and other segments were collectively estimated to be worth $82.3 million in 2010 and $95.5 million in 2011. BCC expects the market to grow to $346.5 million by 2016, a CAGR of 29.4% since 2011, and to reach nearly $630 million by 2021, a CAGR of 12.7% between 2016 and 2021.

Metamaterials: Technologies and Global Markets

Published:January 2012
No. of Pages: 150

STUDY GOALS AND OBJECTIVES

Metamaterials offer seemingly endless possibilities, but it is unlikely that all of these possibilities will become reality. The goal of this report, which is an update of an earlier BCC Research report published in 2008, is to survey emerging metamaterials technologies and applications, identify those that are most likely to achieve significant commercial sales in the next 5 to 10 years, and develop quantitative estimates of potential sales. The report generally avoids futuristic speculation concerning technology applications that might be possible 10 years or further into the future and instead focuses on applications that are expected make it to market by 2021.

The report’s specific objectives, which include identifying the metamaterials with the greatest commercial potential in the 2012 to 2021 time frame, identifying market drivers and evaluating obstacles to their successful commercialization, and projecting their future sales, support this broad goal.

INTENDED AUDIENCE

This report is intended specifically for marketing executives, entrepreneurs, investors, venture capitalists, and other readers who need to know where the emerging metamaterials market is headed over the next 5 to 10 years. The information is organized around specific technologies, but it is largely non-technical in nature and coverage. Therefore, it is less concerned with theory and jargon, and more concerned with products that work, the amount of a particular product the market is likely to purchase, and the price consumers are willing to pay.

The report has not been written specifically for scientists and technologists, but its findings concerning the market for their work, including the availability of government and corporate research funding for different technologies and applications, should be of interest to them as well.

World Plastic Processing Machinery to 2015

This Freedonia industry study, World Plastics Processing Machinery, is priced at $5900. It presents historical demand data through 2010 plus forecasts for 2015 and 2020 by product and primary application for six world regions and 30 countries. The study also details market environment factors, evaluates company market share and profiles global players such as Engel, Haitian International, Husky Injection Molding Systems, Japan Steel Works, KraussMaffei Technologies, Milacron, and Sumitomo Heavy Industries.

Excluded from the scope of this study are auxiliary equipment (such as blenders, dryers, feeders and winders) and secondary equipment used to improve the appearance or usefulness of the final product (like coating, cutting, machining, polishing and printing machinery), except in situations in which machinery is used in both primary and secondary plastics processing. Plastics processing equipment that forms an integral part of a form/fill/seal packaging machine and molds are also excluded.

Plastic Processing Machinery Industry

Published:January 2012
No. of Pages: 392

The major global plastics processing machinery manufacturers are identified and profiled, and the key competitive variables are discussed. The entire report is framed within the world plastics processing machinery industry’s economic, technological and market environments, and therefore environmental variables affecting siding demand (especially building construction expenditures), an important market for plastics, are emphasized.

World market share data by company presented in the “Industry Structure” section are estimated based on consultation with multiple sources. In addition, tabular details may not always add to totals due to rounding.

Construction, consumer/institutional markets to register strongest gains

The construction market will exhibit the strongest gains through 2015, benefiting from acceleration in global construction spending. The consumer/institutional products market will also post above average gains, reflecting rising standards of living. The packaging market will post respectable gains due to rising manufacturing output and consumer demand for packaged products.

Developing nations to spur global market advances

Gains in developing nations will be the driving force behind advances in the global market for plastics processing equipment. China, for example, will account for more than 40 percent of all additional demand through 2015, with growth stimulated by strong increases in plastic manufacturing as industrialization efforts continue and income levels rise. Other nations in Asia with smaller, less developed economies, such as India, Vietnam and Thailand, will also record healthy market gains. In developed areas of the world, most notably Western Europe, the US and Japan, demand will rebound after a period of decline, although sales advances will not be as strong as those in developing nations.

The LTE Infrastructure Market: Vendors, Market Share, Key Trends & Forecasts

As of Q4 2011, thirty eight mobile network operators worldwide had launched fourth-generation (4G) Long Term Evolution (LTE) networks commercially. Despite a slow ramp and spending stall on overall cellular network infrastructure in 2011, the industry is witnessing sustainable spending acceleration for the LTE wireless infrastructure equipment. Key drivers are higher data speeds of up to 20 Mbps, simplified all-IP networks and the commercial availability of more than 200 4G LTE - enabled devices.

This report and its associated database provide an in depth analysis of the LTE Infrastructure market from 2010 to 2015, including revenue projections by vendor, region and equipment type, base station shipments, and key trends within the industry. In addition to the written report, purchasers of this research will receive an Excel spreadsheet consisting of global LTE infrastructure revenue including BTS shipment data.

Purchasers of a Team License of this report will also receive the related research Global Cellular Handset Update: Market, Technology, Vendor, and Application Analysis at no additional charge.

Purchasers of a Company-wide License of this report will also receive the related research report Global LTE Industry Landscape: Adoption, Applications, Deployments and Subscriptions by Region, Country, Spectrum and Operator 2011 - 2015 at no additional charge.

LTE Infrastructure Market

Published:January 2012
No. of Pages: 66




Key Findings:

• LTE revenues have reached over $ 2.1 Billion in 2011, up from $ 0.6 Billion in 2010
• As of Q4'2011 the North America region accounts for over 42 % of the total LTE Infrastructure revenue
• Ericsson and Alcatel Lucent are likely to lead the market with present market shares of over 35 % and 27 % respectively LTE infrastructure Industry respectively in 2011
• From a regional perspective, the market share will drastically shift from a North American lead market to the Asia Pacific region, which will account for over 68 % of the revenue by 2015
• Global 2G/3G/4G cellular network infrastructure revenues are set to reach over $ 51 Billion by 2015 up from $46 Billion in 2010 at a CAGR of 5%, with LTE accounting for more than 20 % of the revenue share

Report Benefits:

• Provides a comprehensive analysis of the technology and key trends emerging in the LTE Infrastructure market
• Provides revenue, market share figures and profiles for major and specialized LTE infrastructure vendors for 2010 and 2011, and forecasts up to 2015
• Provides revenue, base station shipment and market share figures for LTE equipment split by equipment type (E-UTRAN, EPC), technology (FDD, TDD) and region

Residential Generators, 3rd Edition - U.S. Market and World Data

Residential Generator, 3rd Edition - U.S. and World Markets is the third installment of SBI Energy's series of reports that have chronicled global markets for consumer generators (lower output generators for residential and commercial applications) since 2002. The highly-competitive, billion-dollar U.S. market for residential engine-generator sets (gensets) has ratcheted up in volume on successive consumer demand factors including consumer Y2K anxieties, major regional outage events (landed hurricanes, winter storms, etc.), and the boom and bust of the housing market. Grid instability and weather volatility strongly influence year-to-year consumer demand for potable and standby (stationary) gensets. Fluctuating domestic demand has led prominent U.S. consumer genset suppliers overseas to secondary residential markets in Latin America, Europe and Asia also in play for export-reliant Japanese and Chinese genset manufacturers.

SBI Energy's latest report provides a review of global and regional residential generator markets in the past ten years, detailed assessments of the U.S. consumer genset industry and residential market, and up-to-date coverage of the latest industry events, including Hurricane Irene. Global market demand for residential generators is quantified and projections for growth in demand are provided. Historical and projected market volumes are provided globally, regionally and for key countries (United States, Canada, Australia, Japan, China and others). Key factors are expertly analyzed: long-term meteorological trends, grid integrity and outage events, competition from emerging alternative and renewable energy technologies, consumer purchasing and property investment trends, and genset purchaser and owner demographics in the United States.

Residential Generators Market

Published:January 2012
No. of Pages: 195

Report Methodology

The data, assessments and analysis provided in Residential Generator, 3rd Edition - U.S. and World Markets is based on primary and secondary research. Primary research included interviews with firms involved in the manufacture, distribution and sales of genset products as well as analysts with insights into the genset industry. Secondary research included the comprehensive review and consolidation of U.S. and foreign trade data, SEC filings from relevant publicly-traded companies, other governmental sources, company literature, other analyst estimations and calculations, and other SBI Energy publications.

How You'll Benefit from This Report

If your company is already doing business in on-site residential generation, or is considering entering the market, you will find this report invaluable. You will gain a thorough understanding of the current global market for residential engine-generator products and technologies, as well as projected market demand and trends through 2021.

This report will help:

• Marketing managers understand the market forces shaping the market for residential generators and identify market opportunities.
• Research and development professionals stay on top of competitor initiatives and explore demand for residential power generation products.
• Business development executives understand the dynamics of the market and identify possible partnerships.
• Information and research center librarians provide market researchers, product managers, and other colleagues with the vital information they need to do their jobs more effectively.

Power Boilers in Asia Pacific - Market Size, Average Pricing, Equipment Market Share and Competitive Landscape Analysis to 2020

This report analyzes the Asia Pacific power boiler market in terms of power boiler units sold, power boiler revenues and market share of companies in terms of revenues. It also discusses the key drivers and restraints impacting the market. The report provides an in depth analysis of key Asia-Pacific power boiler markets–India, China, Japan, Taiwan, Indonesia, South Korea, Philippines Vietnam, and Australia. It provides data and analysis related to the market size, revenues, market share, average price and the regulations in each of these countries. The report also provides SWOT analysis of five key power boiler manufacturing companies in Asia Pacific region.

Power Boilers Market in Asia Pacific 

Published:January 2012
No. of Pages: 139

Scope

• Data on the revenue generated from power boiler sales for the leading countries of Asia-Pacific region.
• Data on the pricing and volume analysis for power boiler, globally, Asia-Pacific region and for leading countries of Asia-Pacific like India, China, Japan, Taiwan, Indonesia, South Korea, Philippines, Vietnam and Australia.
• Revenue forecast at the global, regional and country level.
• Detailed market share analysis of top market participants such as Shanghai Electric Group Corporation, Bharat Heavy Electricals Limted, Donfang Electric Corporation Limted, Mitsubhishi Heavy Industries Limited, and Foster Wheeler AG
• Power market regulations for key countries
• Data sourced from proprietary databases and primary interviews with key participants across the value chain

Reasons to buy

• Facilitate decision-making based on strong historic and forecast data for the power boiler market.
• Develop strategies based on the latest pricing trends, market shares and revenue growth.
• Position yourself to gain the maximum advantage in the power boiler market’s growth potential.
• Identify key partners and business development avenues.
• Respond to your competitors’ business structure, strategy and prospects.

On-trend Foodservice Concepts

Innovation in the foodservice market can often trickle down to the retail sector at a later date. Consumers visit foodservice outlets for many reasons, such as the desire for better quality food, to sample something new, added convenience etc. Eventually, shoppers expect these innovations to be available when buying groceries. This means it is vital manufacturers monitor hot trends in foodservice.

This report looks at the hot trends emerging in the foodservice sector. From these, Datamonitor has identified best practice examples of each trend, the key consumer need states being met, and how grocery manufacturers can capitalize on each trend.

Features and benefits

• Enables operators in the foodservice sector to see what hot trends are emerging and best practice examples of the trends in action.
• Identifies how consumer attitudes towards food and drink are evolving, and what new need states are emerging.
• Highlights new opportunities for grocery manufacturers to differentiate from competitors with new product offerings.

On-trend Foodservice Concepts

Published:January 2012

Highlights

Innovation is happening in the foodservice sector in terms of the food being served, the setting of the venue, or the way in which the food is delivered. For each innovation, grocery manufacturers can identify the underlying consumer need state being addressed, and from this innovate through product formulation, marketing, packaging etc.

The report has identified a number of best practice examples of new product launches in the grocery sector to accommodate recommendations made for manufacturers. These new products and the underlying key consumer need states that they meet, should be used as inspiration for new product development in the future.

Your key questions answered
What are the hot trends emerging in the foodservice sector?
How can grocery manufacturers capitalize on emerging trends in the foodservice sector?

Nuclear Condensate and Feed Water Pumps - Global Market Size, Pricing, Regional Analysis and Competitive Landscape to 2020

GlobalData’s latest report, “Nuclear Condensate and Feed Water Pumps - Global Market Size, Pricing, Regional Analysis and Competitive Landscape to 2020” gives detailed information on the global nuclear condensate and feed water pumps market and provides historical and forecast data for the nuclear condensate and feed water pumps. The research analyzes trends in the global nuclear condensate and feed water pumps market and gives detailed analysis of the leading countries in the business.The growing demand for electricity and new emission abatement targets have led to the resurgence of nuclear power despite increased concerns about the safety of nuclear power after the Fukushima nuclear disaster. Most of the countries with significant nuclear power facilities are expanding their nuclear fleet, whilst another 30 countries are becoming emerging nuclear power countries

Nuclear Condensate and Feed Water Pumps

Published: January 2012
No. of Pages: 155

                 

 

Scope

• A brief overview of the nuclear condensate and feed water pumps market and the factors which impact the market.
• Countries covered include the US, Canada, France, Russia, Germany, Ukraine, the UK, Japan, South Korea, China and India.
• Historical and forecast data of the total demand for nuclear condensate and feed water pumps and their market values.
• Review of key market trends, drivers and restraints for the nuclear condensate and feed water pumps industry.
• Information on key players Clyde Union, Sulzer Pumps, Flowserve Corporation, KSB Pumps and Hitachi Plant Technologies Ltd.

Reasons to buy

• Facilitate decision-making based on strong historic and forecast data for the nuclear turbine generators market.
• Position yourself to gain maximum advantage from the nuclear turbine generator market’s growth potential.
• Identify key partners and business development avenues.
• Respond to your competitors’ business structures, strategies and prospects.

Europe In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

GlobalData’s new report, “Europe In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the  Europe In Vitro Diagnostics  market – France, Germany, Italy, Spain and United Kingdom. The report provides value (USD million) data for all the market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants.

Europe In Vitro Diagnostics Market Outlook to 2017

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope

• Countries covered include France, Germany, Italy, Spain and United Kingdom.
• Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
• Annualized market revenues (USD million) data for each of the market categories in each of the country. Data from 2003 to 2010, forecast forward for 7 years to 2017.
• 2010 company shares and distribution shares data for each of the market categories and countries.
• Global corporate-level profiles of key companies operating within the Europe In Vitro Diagnostics market.
• Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., bioMerieux S.A., Ortho-Clinical Diagnostics Inc. and others.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Europe In Vitro Diagnostics competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 12
2 Introduction 14
2.1 What is This Report About? 14
3 In Vitro Diagnostics in Europe 15
3.1 In Vitro Diagnostics Cross Country Comparison, USD Actual, 2003-2017 15
3.2 In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, 2003-2017 16
3.3 In Vitro Diagnostics, Europe, Company share (2009-2010) 24
4 In Vitro Diagnostics In Germany 26
4.1 In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, 2003-2017 26
4.2 In Vitro Diagnostics, Germany, Distribution Share (2009-2010) 32
4.3 In Vitro Diagnostics, Germany, Company share (2009-2010) 36
5 In Vitro Diagnostics In France 52
5.1 In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, 2003-2017 52
5.2 In Vitro Diagnostics, France, Distribution Share (2009-2010) 58
5.3 In Vitro Diagnostics, France, Company share (2009-2010) 62
6 In Vitro Diagnostics In Italy 78
6.1 In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, 2003-2017 78
6.2 In Vitro Diagnostics, Italy, Distribution Share (2009-2010) 84
6.3 In Vitro Diagnostics, Italy, Company share (2009-2010) 88
7 In Vitro Diagnostics In United Kingdom 104
7.1 In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, 2003-2017 104
7.2 In Vitro Diagnostics, United Kingdom, Distribution Share (2009-2010) 110
7.3 In Vitro Diagnostics, United Kingdom, Company share (2009-2010) 114
8 In Vitro Diagnostics In Spain 130
8.1 In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, 2003-2017 130
8.2 In Vitro Diagnostics, Spain, Distribution Share (2009-2010) 136
8.3 In Vitro Diagnostics, Spain, Company Share (2009-2010) 140
9 Overview of Key Companies in Europe In Vitro Diagnostics Market 156
9.1 F. Hoffmann-La Roche Ltd. 156
9.2 Siemens Healthcare 157
9.3 Abbott Laboratories 158
9.4 Beckman Coulter, Inc. 159
9.5 bioMerieux S.A. 160
9.6 Ortho-Clinical Diagnostics Inc. 161
9.7 Sysmex Corporation 162
9.8 Bio-Rad Laboratories, Inc. 162
9.9 Becton, Dickinson and Company 162
9.10 DiaSorin S.p.A 163
9.11 Phadia AB 163
9.12 Alere Inc. 163
9.13 DIAGNOSTICA STAGO, Inc. 164
9.14 Qiagen N.V. 164
9.15 Gen-Probe Incorporated 164
9.16 HORIBA, Ltd. 165
9.17 Thermo Fisher Scientific Inc. 165
9.18 Grifols, S.A. 165
9.19 PerkinElmer, Inc. 166
9.20 Danaher Corporation 166
9.21 The Elitech Group 166
9.22 BioSystems International 167
9.23 Life Technologies Corporation 167
9.24 Immucor, Inc. 167
9.25 Hologic, Inc. 168
9.26 Cellestis Limited 168
9.27 Atlas Medical 168
10 In Vitro Diagnostics Market Pipeline Products 169
10.1 Clinical Chemisty Market Pipeline Products 169
10.2 Immuno Chemistry Market Pipeline Products 172
10.3 Haematology Market Pipeline Products 175
10.4 Infectious Immunology Market Pipeline Products 177
10.5 Microbiology Culture Market Pipeline Products 181
10.6 Histology and Cytology Market Pipeline Products 182
10.7 Genetic Testing Market Pipeline Products 183
11 Financial Deals Landscape 188
11.1 Merger 188
11.2 Acquisition 189
11.3 Partnerships 220
12 Recent Developments 291
12.1 Strategy And Business Planning 291
12.2 Legal and Regulatory 308
12.3 Government and Public Interest 313
12.4 Product News 329
13 Appendix 364
13.1 Definitions of Markets Covered in the Report 365
13.2 Research Methodology 367
13.3 Secondary Research 367
13.4 Primary Research 368
13.5 Models 368
13.6 Forecasts 369
13.7 Expert Panels 369
13.8 GlobalData Consulting 369
13.9 Currency Conversion 370
13.10 Contact Us 370
13.11 Disclaimer 370
List of Tables
Table 1:In Vitro Diagnostics, Cross Country Comparison, USD Actual, 2003-2017 25
Table 2:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, 2003-2017 27
Table 3:In Vitro Diagnostics, Europe, Cross-Category Analysis, 2003-2017 29
Table 4:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, Historic, 2003-2010 31
Table 5:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 33
Table 6:In Vitro Diagnostics, Europe, Company Share by Revenue ($m), USD Actual, 2009-2010 35
Table 7:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, 2003-2017 37
Table 8:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, Historic, 2003-2010 39
Table 9:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 41
Table 10:Clinical Chemistry, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 42
Table 11:Genetic Testing, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 42
Table 12:Haematology, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 43
Table 13:Histology And Cytology, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 43
Table 14:Immuno Chemistry, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 44
Table 15:Infectious Immunology, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 44
Table 16:Microbiology Culture, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 45
Table 17:In Vitro Diagnostics, Germany, Company share by Revenue ($m), USD Actual, 2009-2010 47
Table 18:Clinical Chemistry, Germany, Company share by Revenue ($m), USD Actual 2009-2010 49
Table 19:Genetic Testing, Germany, Company share by Revenue ($m), USD Actual 2009-2010 51
Table 20:Haematology, Germany, Company share by Revenue ($m), USD Actual 2009-2010 53
Table 21:Histology And Cytology, Germany, Company share by Revenue ($m), USD Actual 2009-2010 55
Table 22:Immuno Chemistry, Germany, Company share by Revenue ($m), USD Actual 2009-2010 57
Table 23:Infectious Immunology, Germany, Company share by Revenue ($m), USD Actual 2009-2010 59
Table 24:Microbiology Culture, Germany, Company share by Revenue ($m), USD Actual 2009-2010 61
Table 25:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, 2003-2017 63
Table 26:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, Historic, 2003-2010 65
Table 27:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 67
Table 28:Clinical Chemistry, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 68
Table 29:Genetic Testing, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 68
Table 30:Haematology, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 69
Table 31:Histology And Cytology, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 69
Table 32:Immuno Chemistry, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 70
Table 33:Infectious Immunology, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 70
Table 34:Microbiology Culture, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 71
Table 35:In Vitro Diagnostics, France, Company share by Revenue ($m), USD Actual, 2009-2010 73
Table 36:Clinical Chemistry, France, Company share by Revenue ($m), USD Actual 2009-2010 75
Table 37:Genetic Testing, France, Company share by Revenue ($m), USD Actual 2009-2010 77
Table 38:Haematology, France, Company share by Revenue ($m), USD Actual 2009-2010 79
Table 39:Histology And Cytology, France, Company share by Revenue ($m), USD Actual 2009-2010 81
Table 40:Immuno Chemistry, France, Company share by Revenue ($m), USD Actual 2009-2010 83
Table 41:Infectious Immunology, France, Company share by Revenue ($m), USD Actual 2009-2010 85
Table 42:Microbiology Culture, France, Company share by Revenue ($m), USD Actual 2009-2010 87
Table 43:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, 2003-2017 89
Table 44:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, Historic, 2003-2010 91
Table 45:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 93
Table 46:Clinical Chemistry, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 94
Table 47:Genetic Testing, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 94
Table 48:Haematology, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 95
Table 49:Histology And Cytology, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 95
Table 50:Immuno Chemistry, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 96
Table 51:Infectious Immunology, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 96
Table 52:Microbiology Culture, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 97
Table 53:In Vitro Diagnostics, Italy, Company share by Revenue ($m), USD Actual, 2009-2010 99
Table 54:Clinical Chemistry, Italy, Company share by Revenue ($m), USD Actual 2009-2010 101
Table 55:Genetic Testing, Italy, Company share by Revenue ($m), USD Actual 2009-2010 103
Table 56:Haematology, Italy, Company share by Revenue ($m), USD Actual 2009-2010 105
Table 57:Histology And Cytology, Italy, Company share by Revenue ($m), USD Actual 2009-2010 107
Table 58:Immuno Chemistry, Italy, Company share by Revenue ($m), USD Actual 2009-2010 109
Table 59:Infectious Immunology, Italy, Company share by Revenue ($m), USD Actual 2009-2010 111
Table 60:Microbiology Culture, Italy, Company share by Revenue ($m), USD Actual 2009-2010 113
Table 61:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, 2003-2017 115
Table 62:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Historic, 2003-2010 117
Table 63:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 119
Table 64:Clinical Chemistry, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 120
Table 65:Genetic Testing, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 120
Table 66:Haematology, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 121
Table 67:Histology And Cytology, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 121
Table 68:Immuno Chemistry, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 122
Table 69:Infectious Immunology, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 122
Table 70:Microbiology Culture, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 123
Table 71:In Vitro Diagnostics, United Kingdom, Company share by Revenue ($m), USD Actual, 2009-2010 125
Table 72:Clinical Chemistry, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 127
Table 73:Genetic Testing, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 129
Table 74:Haematology, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 131
Table 75:Histology And Cytology, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 133
Table 76:Immuno Chemistry, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 135
Table 77:Infectious Immunology, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 137
Table 78:Microbiology Culture, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 139
Table 79:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, 2003-2017 141
Table 80:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, Historic, 2003-2010 143
Table 81:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 145
Table 82:Clinical Chemistry, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 146
Table 83:Genetic Testing, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 146
Table 84:Haematology, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 147
Table 85:Histology and Cytology, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 147
Table 86:Immuno Chemistry, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 148
Table 87:Infectious Immunology, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 148
Table 88:Microbiology Culture, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 149
Table 89:In Vitro Diagnostics, Spain, Company Share by Revenue ($m), USD Actual, 2009-2010 151
Table 90:Clinical Chemistry, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 153
Table 91:Genetic Testing, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 155
Table 92:Haematology, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 157
Table 93:Histology and Cytology, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 159
Table 94:Immuno Chemistry, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 161
Table 95:Infectious Immunology, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 163
Table 96:Microbiology Culture, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 165
Table 97: Clinical Chemisty Market Pipeline Products 179
Table 98: Immuno Chemistry Market Pipeline Products 182
Table 99: Haematology Market Pipeline Products 185
Table 100: Infectious Immunology Market Pipeline Products 187
Table 101: Microbiology Culture Market Pipeline Products 191
Table 102: Histology and Cytology Market Pipeline Products 192
Table 103: Genetic Testing Market Pipeline Products 193
Table 104:Centre For Molecular Medicine And Human Genetics Unit Merge To Form IGMM 198
Table 105:Roche To Acquire Verum Diagnostica For $17.4 Million 199
Table 106:Lepu Medical Technology To Acquire 40% Stake In Comed For $1.9 Million 200
Table 107:Alere Receives Valid Acceptance For Revised Offer To Acquire Axis-Shield For $385 Million 201
Table 108:Grifols Acquires Remaining 51% Stake In Lateral-Medion 203
Table 109:PZ Cormay Acquires 98.62% Stake In Audit Diagnostics 204
Table 110:Roche Completes Acquisition Of mtm laboratories 205
Table 111:bioMerieux Acquires Argene 207
Table 112:Qiagen To Acquire 61% Stake In IPSOGEN 208
Table 113:Lab21 Acquires Myconostica 210
Table 114:Thermo Fisher Completes Acquisition Of Phadia 211
Table 115:bioMerieux Completes Acquisition Of AES Laboratoire 213
Table 116:Ion Beam Applications Acquires 25% Stake In PET Net 215
Table 117:Qiagen Completes Acquisition Of Cellestis 216
Table 118:Techne Acquires Boston Biochem And Boston Biochem 218
Table 119:Merck Acquires heipha Dr. Muller And Related Assets From Biotest 219
Table 120:Agilent Technologies Acquires Lab901 221
Table 121:PerkinElmer Acquires Chemagen Biopolymer 223
Table 122:Imperial Innovations Acquires Minority Stake In Molecular Vision 225
Table 123:AlphaHelix Molecular Diagnostics Acquires Techtum Lab 226
Table 124:ERBA DIAGNOSTICS MANNHEIM Acquires Diasis Diagnostic Systems 227
Table 125:Addtech Life To Acquire Electra-Box Diagnostica 228
Table 126:Lab21 Acquires Microgen Bioproducts 229
Table 127:Global BioDiagnostics Extends Co-Development Agreement With Foundation for Innovative New Diagnostics 230
Table 128:Sony DADC Enters Into Co-Development Agreement With Axela 231
Table 129:Roche Enters Into Joint Venture Agreement With Swiss Federal Institute of Technology, University of Zurich And University Hospital Zurich 232
Table 130:Sony DADC BioSciences Enters Into Co-Development Agreement With Maven Biotechnologies 234
Table 131:Abbott Laboratories Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals 235
Table 132:Dolomite Enters Into Co-Development Agreement With Clearbridge BioMedics 236
Table 133:SuperNova Diagnostics Enters Into Co-Development Agreement With Concile 237
Table 134:Dako Enters Into Co-Development Agreement With Bristol-Myers 238
Table 135:Transgenomic Enters Into Distribution Agreement With ScreenCell 239
Table 136:Oxford Gene Technology Enters Into Co-Development Agreement With Abcodia 240
Table 137:Horizon Discovery Enters Into Co-Development Agreement With Promega 241
Table 138:Sony DADC Enters Into Co-Development Agreement With Anagnostics Bioanalysis 242
Table 139:Life Technologies Enters Into Co-Development Agreement With GlaxoSmithKline Biologicals 243
Table 140:Axis-Shield Enters Into Co-Development Agreement With Siemens Healthcare Diagnostics 244
Table 141:TcLand Expression Enters Into Co-Development Agreement With Radboud University Nijmegen 245
Table 142:Generation Scotland Enters Into Co-Development Agreement With Arrayjet 246
Table 143:Accelr8 Technology Amends Licensing Agreement With SCHOTT 247
Table 144:Orion Genomics Enters Into Licensing Agreement With QIAGEN 248
Table 145:Almac Group Enters Into Research Agreement With Queen’s University Belfast 249
Table 146:QIAGEN Enters Into Co-Development Agreement With Eli Lilly 250
Table 147:Skyline Diagnostics Enters Into Research Agreement With Clavis Pharma 251
Table 148:Lumora Enters Into Licensing Agreement With 3M 252
Table 149:Quanterix Enters Into Co-Development Agreement With STRATEC Biomedical 253
Table 150:Sequenom Enters Into Licensing Agreement With LifeCodexx 254
Table 151:Enigma Diagnostics Enters Into Co-Development Agreement With GlaxoSmithKline 255
Table 152:BD Diagnostics Enters Into Co-Development Agreement With Lab21 256
Table 153:Hycor Biomedical Signs Licensing Agreement With Eurospital 257
Table 154:Hycor Biomedical Signs Licensing Agreement With Axis-Shield 258
Table 155:Quanterix Enters Into Co-Development Agreement With Sony DADC 259
Table 156:Mayo Medical Laboratories Enters Into Licensing Agreement With Qiagen 260
Table 157:Proteome Sciences Enters Into Collaboration With Buck Institute 261
Table 158:Proteome Sciences Enters Into Co-Development Agreement With H. Lee Moffitt Cancer Center 262
Table 159:Skyline Diagnostics Enters Into Research Collaboration With Johnson & Johnson Pharmaceutical 263
Table 160:Metamark Genetics Enters Into Co-Development Agreement With Definiens 264
Table 161:Bruker Daltonics Enters Into Distribution Agreement With Francisco Soria Melguizo 265
Table 162:Roche Enters Into Collaboration With Evotec 266
Table 163:Life Technologies, Oxford Biomedical Research Centre, AstraZeneca And ORD Enter Into Co-Development Agreement 267
Table 164:ResearchDx Enters Into Partnership With CompanDX 268
Table 165:Source BioScience Enters Into Co-Development Agreement With Barts Cancer Institute And Illumina 269
Table 166:University of Geneva, Hopitaux Universitaires de Geneve, SIB And Roche Form Partnership 270
Table 167:F. Hoffmann-La Roche Enters Into Co-Development Agreement With Merck 271
Table 168:Roche Enters Into Co-Development Agreement With Clovis Oncology 272
Table 169:Roche Applied Science Enters Into Partnership With TIB MOLBIOL 273
Table 170:Pacific Edge Biotechnology Enters Into Licensing Agreement With Oryzon Genomics 274
Table 171:EKF Diagnostics Enters Into Distribution Agreement With Alere 275
Table 172:AbD Serotec Enters Into Licensing Agreement With Proteomika 276
Table 173:BD Diagnostic Enters Into Co-Development Agreement With Diagenode 277
Table 174:Atonomics Enters Into An Agreement With Beckman Coulter 278
Table 175:Royal Philips Electronics Enters Into Co-Development Agreement With NEC 279
Table 176:Precision System Science Enters Into Co-Development Agreement With Biotrin International 280
Table 177:Genmab Enters Into Research Collaboration With Seattle Genetics 281
Table 178:Biofortuna Enters Into Distribution Agreement With Abbott 282
Table 179:Advanced Cell Diagnostics Enters Into Co-Development Agreement With Definiens 283
Table 180:DNA Genotek Enters Into Distribution Agreement With Abyntek Biopharma 284
Table 181:BioFocus Enters Into An Agreement With Almac Group 285
Table 182:Seegene Enters Into An Agreement With Molzym 286
Table 183:Dako Denmark Enters Into Co-Development Agreement With Epitomics 287
Table 184:Accelrys Enters Into Co-Development Agreement With Oxford Nanopore 288
Table 185:Ascent Scientific Enters Into Licensing Agreement With Children’s Memorial Hospital And The University Of Newcastle 289
Table 186:Genomic Expression Enters Into An Agreement With Copenhagen University, Beijing Genome Institute And Bavarian Nordic 290
Table 187:BioPorto Enters Into Licensing Agreement With Instrumentation Laboratory 291
Table 188:Oxford Medical Diagnostics Enters Into Co-Marketing Agreement With V&F Analyse 292
Table 189:FIND Enters Into An Agreement With Global BioDiagnostics 293
Table 190:Epigenomics Enters Into Research Licensing Agreement With QIAGEN 294
Table 191:CompanDX Enters Into Agreement With Clinical Reference Laboratory 295
Table 192:Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics 296
Table 193:PROGEN Biotechnik Enters Into Distribution Agreement With Mitsubishi Chemical 297
Table 194:NorDiag Enters Into Agreement With Precision System Science 298
Table 195:Consort Medical Enters Into Co-Development Agreement With Atlas Genetics 299
Table 196:Cepheid Enters Into Co-Development Agreement With FIND 300
Table 197: USD to Local Currency, Europe, Average Exchange Rate 2003-2010 380
List of Figures
Figure 1:In Vitro Diagnostics, Cross Country Comparison, USD Actual, 2003-2017 25
Figure 2:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, 2003-2017 26
Figure 3:In Vitro Diagnostics, Europe, Cross-Category Analysis, 2003-2017 28
Figure 4:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, Historic, 2003-2010 30
Figure 5:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 32
Figure 6:In Vitro Diagnostics, Europe, Company share (%), 2010 34
Figure 7:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, 2003-2017 36
Figure 8:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, Historic, 2003-2010 38
Figure 9:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 40
Figure 10:In Vitro Diagnostics, Germany, Company Share (%), 2010 46
Figure 11:Clinical Chemistry, Germany, Company Share (%), 2010 48
Figure 12:Genetic Testing, Germany, Company Share (%), 2010 50
Figure 13:Haematology, Germany, Company Share (%), 2010 52
Figure 14:Histology And Cytology, Germany, Company Share (%), 2010 54
Figure 15:Immuno Chemistry, Germany, Company Share (%), 2010 56
Figure 16:Infectious Immunology, Germany, Company Share (%), 2010 58
Figure 17:Microbiology Culture, Germany, Company Share (%), 2010 60
Figure 18:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, 2003-2017 62
Figure 19:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, Historic, 2003-2010 64
Figure 20:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 66
Figure 21:In Vitro Diagnostics, France, Company Share (%), 2010 72
Figure 22:Clinical Chemistry, France, Company share (%), 2010 74
Figure 23:Genetic Testing, France, Company share (%), 2010 76
Figure 24:Haematology, France, Company share (%), 2010 78
Figure 25:Histology And Cytology, France, Company share (%), 2010 80
Figure 26:Immuno Chemistry, France, Company share (%), 2010 82
Figure 27:Infectious Immunology, France, Company share (%), 2010 84
Figure 28:Microbiology Culture, France, Company share (%), 2010 86
Figure 29:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, 2003-2017 88
Figure 30:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, Historic, 2003-2010 90
Figure 31:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 92
Figure 32:In Vitro Diagnostics, Italy, Company share (%), 2010 98
Figure 33:Clinical Chemistry, Italy, Company share (%), 2010 100
Figure 34:Genetic Testing, Italy, Company share (%), 2010 102
Figure 35:Haematology, Italy, Company share (%), 2010 104
Figure 36:Histology And Cytology, Italy, Company share (%), 2010 106
Figure 37:Immuno Chemistry, Italy, Company Share (%), 2010 108
Figure 38:Infectious Immunology, Italy, Company share (%), 2010 110
Figure 39:Microbiology Culture, Italy, Company share (%), 2010 112
Figure 40:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, 2003-2017 114
Figure 41:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Historic, 2003-2010 116
Figure 42:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 118
Figure 43:In Vitro Diagnostics, United Kingdom, Company share (%), 2010 124
Figure 44:Clinical Chemistry, United Kingdom, Company share (%), 2010 126
Figure 45:Genetic Testing, United Kingdom, Company share (%), 2010 128
Figure 46:Haematology, United Kingdom, Company share (%), 2010 130
Figure 47:Histology And Cytology, United Kingdom, Company share (%), 2010 132
Figure 48:Immuno Chemistry, United Kingdom, Company share (%), 2010 134
Figure 49:Infectious Immunology, United Kingdom, Company share (%), 2010 136
Figure 50:Microbiology Culture, United Kingdom, Company share (%), 2010 138
Figure 51:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, 2003-2017 140
Figure 52:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, Historic, 2003-2010 142
Figure 53:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 144
Figure 54:In Vitro Diagnostics, Spain, Company Share (%), 2010 150
Figure 55:Clinical Chemistry, Spain, Company Share (%), 2010 152
Figure 56:Genetic Testing, Spain, Company Share (%), 2010 154
Figure 57:Haematology, Spain, Company Share (%), 2010 156
Figure 58:Histology and Cytology, Spain, Company Share (%), 2010 158
Figure 59:Immuno Chemistry, Spain, Company Share (%), 2010 160
Figure 60:Infectious Immunology, Spain, Company Share (%), 2010 162
Figure 61:Microbiology Culture, Spain, Company Share (%), 2010 164
Figure 62:F. Hoffmann-La Roche Ltd., Company Share (%), Europe In Vitro Diagnostics Market, 2010 166
Figure 63:Siemens Healthcare, Company Share (%), Europe In Vitro Diagnostics Market, 2010 167
Figure 64:Abbott Laboratories, Company Share (%), Europe In Vitro Diagnostics Market, 2010 168
Figure 65:Beckman Coulter, Inc., Company Share (%), Europe In Vitro Diagnostics Market, 2010 169
Figure 66:bioMerieux S.A., Company Share (%), Europe In Vitro Diagnostics Market, 2010 170
Figure 67:Ortho-Clinical Diagnostics Inc., Company Share (%), Europe In Vitro Diagnostics Market, 2010 171